Predictive value of serum apolipoprotein B/LDL-cholesterol ratio in cardiometabolic risk: Population-based cohort study

Clinical Biochemistry

Volumn 43, Issue 18, 2010, Pages 1381-1386

  Onat, Altan ^a   Can, Günay ^a   Çiçek, Gökhan ^b   Ayhan, Erkan ^b   Doǧan, Yüksel ^c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c Bakirkoy Sadi Konuk Training and Research Hospital   (Turkey)

Author keywords

Coronary heart disease; Diabetes type 2; Insulin resistance; LDL particle number and size; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIET RESTRICTION; DYSLIPIDEMIA; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION; PREDICTION AND FORECASTING; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

ADULT; APOLIPOPROTEINS B; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY DISEASE; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TURKEY;

EID: 78149496693     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.08.027     Document Type: Article

References (31)

1. Austin M.A., King M.C., Vranizan K.M., Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495-506.
2. Stampfer M.J., Krauss R.M., Ma J., et al. A prospective study of triglyceride level, low-density particle diameter, and risk of myocardial infarction. JAMA 1996, 276:882-888.
3. St-Pierre A.C., Cantin B., Dagenais G.R., et al. Low-density lipoprotein subfractions and the long-term risk in ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005, 25:553-558.
4. Rizzo M., Berneis K. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?. J Ather Thromb 2005, 12:237-239.
5. Rizzo M., Berneis K. Low-density-lipoproteins size and cardiovascular risk assessment. QJM. Int J Med 2006, 99:1-14.
6. Sniderman A., Scantlebury T., Cianflone K. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001, 135:447-459.
7. Mora S., Otvos J.D., Rifai N., et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119:931-939.
8. Sung K.C., Hwang S.T. Association between insulin resistance and apolipoprotein B in normoglycemic Koreans. Atherosclerosis 2005, 180:161-169.
9. Sattar N., Williams K., Sniderman A.D., et al. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation 2004, 110:2687-2693.
10. Swinkels D.W., Demacker P.N., Hendricks J.C., Van't Laar A. Low density lipoprotein subfractions and relationship to other risk factors for coronary artery disease in healthy individuals. Atherosclerosis 1989, 9:604-613.
11. Kathiresan S., Otvos J.D., Sullivan L.M., et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006, 113:20-29.
12. Onat A., Ceyhan K., Başar Ö., et al. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels-a prospective and cross-sectional evaluation. Atherosclerosis 2002, 165:285-292.
13. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001, 156:1-10.
14. Genuth S., Alberti K.G., Bennett P., et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diab Care 2003, 26:3160-3167.
15. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
16. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
17. Onat A., Uyarel H., Hergenç G., et al. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007, 191:182-190.
18. Onat A., Sari I., Hergenç G., et al. Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study. Metabolism 2007, 56:348-356.
19. Mather K.J., Hunt A.E., Steinberg H.O., et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 2001, 86:5457-5464.
20. Rose G., Blackburn H., Gillum R.F., Prineas R.J. Cardiovascular Survey Methods, 2nd Ed. Geneva, Switzerland. WHO 1982, 124-127.
21. Sigurdardottir V., Faberberg B., Hulte J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med 2002, 252:440-447.
22. Georgieva A.M., van Greevenbroek M.M.J., Krauss R.M., et al. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2004, 24:744-749.
23. Goff D.C., D'Agostino R.B., Haffner S.M., Otvos J.D. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations: results from the Insulin Resistance Atherosclerosis Study. Metabolism 2005, 54:264-270.
24. Garvey W.T., Kwon S., Shaughnessy S., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003, 52:453-462.
25. Packard C.J. Triglyceride-rich lipoproteins and the generation of small dense low-density lipoprotein. Biochem Soc Trans 2003, 31:1066-1069.
26. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration.
27. 10 triglyceride/ high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes and vascular events. J Clin Lipidol 2010, 4:89-98.
28. Backes J.M., Gibson C.A. Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein. Ann Pharmacother 2005, 39:523-526.
29. Onat A., Hergenç G., Karabulut A., et al. Serum sex hormone-binding globulin, a determinant of cardiometabolic disorders independent of abdominal obesity and insulin resistance in elderly men and women. Metabolism 2007, 56:1356-1362.
30. Haffner S.M., Laakso M., Miettinen H., et al. Low levels of sex hormone-binding globulin and testosterone are associated with smaller, denser low density lipoprotein in normoglycemic men. J Clin Endocrinol Metab 1996, 81:3697-3701.
31. Onat A., Hergenç G., Bulur S., et al. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2010, 142:72-79.